Lenalidomide (Standard)
Based on 1 Customer Validation
Lenalidomide (Standard) (CC-5013 (Standard)) is the analytical standard of Lenalidomide (HY-A0003). This product is intended for research and analytical applications. Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
For research use only. We do not sell to patients.
- Purity: 99.98%
- CAS No.: 191732-72-6
- Formula: C13H13N3O3
- Molecular Weight:259.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 191732-72-6
-
Appearance Solid
-
Molecular Weight 259.26
-
Formula C13H13N3O3
-
Color White to off-white
-
SMILES
O=C1C2=CC=CC(N)=C2CN1C(C(N3)=O)CCC3=O
-
Synonyms
CC-5013 (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Handling Instructions (2659 KB)
References
[1]. Krönke J, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015 Jul 9;523(7559):183-188. [Content Brief]
[2]. Minnie SA, et al. TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice. The Journal of clinical investigation. 2023 Feb 15;133(4):e157907. [Content Brief]
[3]. Wang Y, et al. TNF-α/HMGB1 inflammation signalling pathway regulates pyroptosis during liver failure and acute kidney injury. Cell Prolif. 2020 Jun;53(6):e12829. [Content Brief]
[4]. Lu G, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (New York, N.Y.). 2014 Jan 17;343(6168):305-9. [Content Brief]
[5]. Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. The AAPS journal. 2012 Dec;14(4):872-82. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lenalidomide (Standard) Related Classifications
HY-A0003R Related Classifications
Powered by Bioz
Keywords
- Lenalidomide (Standard)
- 191732-72-6
- CC-5013 (Standard)
- Reference Standards
- Molecular Glues
- Ligands for E3 Ligase
- IKZF Family
- Casein Kinase
- Apoptosis
- Pyroptosis
- MDM-2/p53
- TNF Receptor
- KG-1 cells
- IKZF3
- cereblon
- M1 macrophages
- myelodysplastic syndrome
- multiple myeloma
- CK1α
- CD8+ T cell
- THP-1 cells
- IKZF1
- Inhibitor
- inhibitor
- inhibit